CA2950754C - Methods and compositions for treatment of disorders with follistatin polypeptides - Google Patents

Methods and compositions for treatment of disorders with follistatin polypeptides Download PDF

Info

Publication number
CA2950754C
CA2950754C CA2950754A CA2950754A CA2950754C CA 2950754 C CA2950754 C CA 2950754C CA 2950754 A CA2950754 A CA 2950754A CA 2950754 A CA2950754 A CA 2950754A CA 2950754 C CA2950754 C CA 2950754C
Authority
CA
Canada
Prior art keywords
follistatin
muscle
fst
polypeptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2950754A
Other languages
English (en)
French (fr)
Other versions
CA2950754A1 (en
Inventor
Ravindra Kumar
Asya Grinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA2950754A1 publication Critical patent/CA2950754A1/en
Application granted granted Critical
Publication of CA2950754C publication Critical patent/CA2950754C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2950754A 2014-06-04 2015-06-04 Methods and compositions for treatment of disorders with follistatin polypeptides Active CA2950754C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007908P 2014-06-04 2014-06-04
US62/007,908 2014-06-04
PCT/US2015/034245 WO2015187977A1 (en) 2014-06-04 2015-06-04 Methods and compositions for treatment of disorders with follistatin polypeptides

Publications (2)

Publication Number Publication Date
CA2950754A1 CA2950754A1 (en) 2015-12-10
CA2950754C true CA2950754C (en) 2021-10-26

Family

ID=54767384

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2950754A Active CA2950754C (en) 2014-06-04 2015-06-04 Methods and compositions for treatment of disorders with follistatin polypeptides

Country Status (12)

Country Link
US (2) US10023621B2 (cg-RX-API-DMAC7.html)
EP (2) EP3152237B1 (cg-RX-API-DMAC7.html)
JP (3) JP6568110B2 (cg-RX-API-DMAC7.html)
KR (4) KR102305109B1 (cg-RX-API-DMAC7.html)
CN (2) CN106795224B (cg-RX-API-DMAC7.html)
AU (2) AU2015269333B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016028520A2 (cg-RX-API-DMAC7.html)
CA (1) CA2950754C (cg-RX-API-DMAC7.html)
EA (2) EA202090632A1 (cg-RX-API-DMAC7.html)
MA (2) MA51075A (cg-RX-API-DMAC7.html)
MX (2) MX382908B (cg-RX-API-DMAC7.html)
WO (1) WO2015187977A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612041B2 (en) 2005-11-23 2009-11-03 Acceleron Pharma Inc. Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
US20100015144A1 (en) 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
EA201590719A1 (ru) 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
JP6568110B2 (ja) 2014-06-04 2019-08-28 アクセルロン ファーマ， インコーポレイテッド フォリスタチンポリペプチドによる障害の処置のための方法および組成物
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
JP2018510637A (ja) * 2015-03-26 2018-04-19 アクセルロン ファーマ， インコーポレイテッド フォリスタチン関連融合タンパク質およびその使用
KR20180137487A (ko) * 2016-03-04 2018-12-27 샤이어 휴먼 지네틱 테라피즈 인크. 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도
US10905766B2 (en) 2017-03-23 2021-02-02 Oregon State University Therapeutic compositions and methods for treatment of muscle wasting diseases
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019046903A1 (en) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT
CN108218985B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用
AU2019233929B2 (en) * 2018-03-16 2025-05-29 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
WO2019178759A1 (zh) * 2018-03-21 2019-09-26 维多利亚生物医学控股股份有限公司 促进局部肌肉增长、减缓或防止局部肌肉萎缩的组合物及其用途
WO2019191204A1 (en) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Follistatin polypeptides for the treatment of muscle contracture
CA3100734A1 (en) * 2018-05-17 2019-11-21 Housey Pharmaceutical Research Laboratories, L.L.C. Inhibition of follistatin
WO2020046466A1 (en) * 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
EP4540274A1 (en) 2022-06-15 2025-04-23 UCB Biopharma SRL Follistatin-fc fusion proteins
CA3259309A1 (en) 2022-06-15 2023-12-21 UCB Biopharma SRL Fusion protein for the prevention, treatment or improvement of kidney disease
WO2024121351A1 (en) * 2022-12-07 2024-06-13 Lodberg Andreas Extracellular matrix binding compounds for the localized loading of therapeutic or diagnostic agents
WO2025157262A1 (en) * 2024-01-25 2025-07-31 Sichuan Real & Best Biotech Co., Ltd. Nucleic acids encoding follistatin and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5182375A (en) 1987-08-28 1993-01-26 The Salk Institute For Biological Studies DNA encoding follistatin
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
ATE288923T1 (de) * 1991-02-08 2005-02-15 Progenics Pharm Inc Cd4-gamma2- und cd4-igg2-chimären
WO1994006456A1 (en) 1992-09-16 1994-03-31 Genentech, Inc. Protection against liver damage by hgf
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
JPH09503673A (ja) 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
GB2306481A (en) 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
DE60027135T2 (de) 1999-01-21 2007-01-11 Metamorphix, Inc. Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
EP1174149A1 (en) 1999-04-19 2002-01-23 Kyowa Hakko Kogyo Co., Ltd. Proliferation inhibitor for androgen-independent tumor
WO2001009368A1 (en) 1999-07-30 2001-02-08 The General Hospital Corporation Follistatin antagonists
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
CN1993048A (zh) * 2002-02-21 2007-07-04 惠氏公司 包含促滤泡素抑制素结构域的蛋白质
JP4429729B2 (ja) 2002-02-21 2010-03-10 ワイス エルエルシー Ｇａｓｐ１；フォリスタチンドメイン含有タンパク質
JP4429728B2 (ja) 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質
ATE474593T1 (de) 2003-03-21 2010-08-15 Celldex Therapeutics Ltd Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
WO2005032578A1 (en) 2003-10-06 2005-04-14 Monash University Therapeutic method
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
EP1778275A2 (en) 2004-08-12 2007-05-02 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
AU2006283725B2 (en) 2005-08-19 2012-02-16 The Trustees Of The University Of Pennsylvania Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
MX2008007324A (es) 2005-12-06 2009-03-04 Amgen Inc Usos de antagonistas de miostatina.
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
EP2097095B1 (en) 2006-11-29 2016-01-27 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
EP2468290B1 (en) 2006-12-18 2015-04-01 Acceleron Pharma, Inc. Activin-ActRII Antagonists for use in treating anemia
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
US20100015144A1 (en) * 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
JP5773868B2 (ja) * 2008-06-26 2015-09-02 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
MX340451B (es) * 2009-09-09 2016-07-08 Acceleron Pharma Inc Antagonistas de actriib y dosificacion y usos de los mismos.
JP5813114B2 (ja) * 2010-08-25 2015-11-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｉｌ−１８ｒ１に対する抗体およびその使用
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
ES2663993T3 (es) 2012-05-17 2018-04-17 Paranta Biosciences Limited Uso de folistatina o de un inhibidor de activina para prevenir o tratar la disfunción del injerto de tejido
ES3049487T3 (en) * 2012-06-27 2025-12-16 Meiragtx Uk Ii Ltd Combination for treating an inflammatory disorder
EA201590719A1 (ru) * 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
WO2014187807A1 (en) * 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
JP6568110B2 (ja) 2014-06-04 2019-08-28 アクセルロン ファーマ， インコーポレイテッド フォリスタチンポリペプチドによる障害の処置のための方法および組成物
JP2018510637A (ja) 2015-03-26 2018-04-19 アクセルロン ファーマ， インコーポレイテッド フォリスタチン関連融合タンパク質およびその使用
JP2020519291A (ja) 2017-05-12 2020-07-02 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 組み換えフォリスタチン−ｆｃ融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用

Also Published As

Publication number Publication date
KR20210119546A (ko) 2021-10-05
US10954279B2 (en) 2021-03-23
EP3152237A4 (en) 2017-11-01
US10023621B2 (en) 2018-07-17
AU2015269333A1 (en) 2016-12-15
US20160185836A1 (en) 2016-06-30
MA51074A (fr) 2020-10-14
MA51075A (fr) 2020-10-14
JP2017518303A (ja) 2017-07-06
KR102132144B1 (ko) 2020-07-09
CN106795224B (zh) 2021-05-18
BR112016028520A2 (pt) 2017-10-24
KR102077286B1 (ko) 2020-02-13
MX382908B (es) 2025-03-13
JP6568110B2 (ja) 2019-08-28
JP6856716B2 (ja) 2021-04-07
EP3721892B1 (en) 2024-05-22
KR20200084064A (ko) 2020-07-09
EP3721892A1 (en) 2020-10-14
MX2021006017A (es) 2021-07-06
KR102305109B1 (ko) 2021-09-27
EA201692529A1 (ru) 2017-05-31
KR20200017548A (ko) 2020-02-18
US20180340013A1 (en) 2018-11-29
MX2016015868A (es) 2017-04-05
AU2020210315A1 (en) 2020-08-27
JP2021095416A (ja) 2021-06-24
JP2019203017A (ja) 2019-11-28
AU2015269333B2 (en) 2020-05-07
CA2950754A1 (en) 2015-12-10
CN106795224A (zh) 2017-05-31
EA202090632A1 (ru) 2020-07-31
EP3152237B1 (en) 2020-04-01
CN113583104A (zh) 2021-11-02
EA035455B1 (ru) 2020-06-18
WO2015187977A1 (en) 2015-12-10
EP3152237A1 (en) 2017-04-12
KR20170005891A (ko) 2017-01-16

Similar Documents

Publication Publication Date Title
US10954279B2 (en) Methods and compositions for treatment of disorders with follistatin polypeptides
US11497792B2 (en) Methods for treatment of Duchenne muscular dystrophy with follistatin polypeptides
US20220169996A1 (en) Truncated actriib-fc fusion proteins
CN105884880B (zh) 由actriib衍生的变体及其用途
HK1236544A1 (en) Methods and compositions for treatment of disorders with follistatin polypeptides
HK1236544B (en) Methods and compositions for treatment of disorders with follistatin polypeptides
HK1238658B (zh) 用促滤泡素抑制素多肽治疗病症的方法和组合物
HK1238658A1 (en) Methods and compositions for treatment of disorders with follistatin polypeptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171213